K. Paleologou

发表

Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α-Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease

P. Aebischer, H. Lashuel, B. Schneider, 2012, The Journal of Neuroscience.

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology

D. Mann, G. Halliday, N. Hattori, 2015, Neurobiology of Disease.

MimickingPhosphorylationatSerine87Inhibitsthe AggregationofHuman-SynucleinandProtectsagainst ItsToxicityinaRatModelofParkinson'sDisease

K. Paleologou, 2012 .

Inhibition of α-Synuclein Fibrillization by Dopamine Is Mediated by Interactions with Five C-Terminal Residues and with E83 in the NAC Region

S. Gustincich, M. Vendruscolo, P. Carloni, 2008, PloS one.

Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

O. El‐Agnaf, G. Irvine, K. Paleologou, 2005, Biochemical Society transactions.

Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils

S. Menon, D. Eliezer, O. El‐Agnaf, 2015, Neurobiology of Disease.

α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

M. Cookson, J. Hardy, D. Mann, 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

K. Johansen, J. Aasly, A. Al-Hayani, 2014, Front. Aging Neurosci..

Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

D. Allsop, J. Court, M. Schlossmacher, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy

O. El‐Agnaf, G. Irvine, K. Paleologou, 2005 .

Phosphorylation of Synucleins by Members of the Polo-like Kinase Family*

E. Masliah, H. Lashuel, M. Zweckstetter, 2009, The Journal of Biological Chemistry.

α-Synuclein aggregation and modulating factors.

O. El‐Agnaf, K. Paleologou, 2012, Sub-cellular biochemistry.

Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions

E. Masliah, P. Aebischer, H. Lashuel, 2010, The Journal of Neuroscience.

Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein*

P. Lansbury, H. Lashuel, D. Eliezer, 2008, Journal of Biological Chemistry.

α Aggregation and Modulating Factors

K. Paleologou, O. Mukhtar, A. El-Agnaf, 2012 .

Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide.

B. Austen, D. Allsop, O. El-Agnaf, 2008, Biochemistry.

Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity*

P. Carrupt, H. Lashuel, M. Zweckstetter, 2010, The Journal of Biological Chemistry.

Hydrogen Peroxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia*

N. Fullwood, D. Allsop, O. El‐Agnaf, 2005, Journal of Biological Chemistry.

Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.

D. Mann, D. Allsop, O. El‐Agnaf, 2008, Brain : a journal of neurology.

Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy

O. El‐Agnaf, S. Usmani, M. Bharath, 2011, Neuroscience.

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

D. Eliezer, O. El‐Agnaf, T. Al‐Tel, 2014, Front. Aging Neurosci..

Parkin Deficiency Delays Motor Decline and Disease Manifestation in a Mouse Model of Synucleinopathy

C. Duyckaerts, A. Brice, M. Hamon, 2009, PloS one.

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts

D. Eliezer, S. Ghanem, N. Vaikath, 2020, BMC Complementary Medicine and Therapies.

A strategy for designing inhibitors of α ‐synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

Nigel J Fullwood, Mark R Cookson, N. Fullwood, 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Parkinson Disease Mutant E46K Enhances α-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo*

E. Masliah, H. Lashuel, S. Tenreiro, 2015, The Journal of Biological Chemistry.

Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay

D. Allsop, O. El-Agnaf, K. Paleologou, 2003, Journal of neurochemistry.

Parkinson Disease Mutant E46K Enhances α-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo*

E. Masliah, H. Lashuel, S. Tenreiro, 2015, The Journal of Biological Chemistry.